The DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index.
Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis
Open accessAbstract
Multiple sclerosis is a complex autoimmune disease, and several therapies for multiple sclerosis have been developed and widely used. However, existing medications for multiple sclerosis were far from satisfactory due to their failure to suppress relapses and alleviate disease progression. Novel drug targets for multiple sclerosis prevention are still needed. We performed Mendelian randomization to explore potential drug targets for multiple sclerosis using summary statistics from the International Multiple Sclerosis Genetics Consortium (nCase = 47 429, nControl = 68 374) and further replicated in UK Biobank (nCase = 1356, nControl = 395 209) and FinnGen cohorts (nCase = 1326, nControl = 359 815). Genetic instruments for 734 plasma and 154 CSF proteins were obtained from recently published genome-wide association studies. The reverse causality detection using bidirectional Mendelian randomization analysis and Steiger filtering, Bayesian co-localization, and phenotype scanning that searched previously reported genetic variant–trait associations were implemented to consolidate the Mendelian randomization findings further. In addition, the protein–protein interaction network was performed to reveal potential associations among proteins and/or present multiple sclerosis medications. At Bonferroni significance (P < 5.63 × 10−5), Mendelian randomization analysis revealed six protein–multiple sclerosis pairs. In plasma, per standard deviation increase in FCRL3, TYMP and AHSG had a protective effect. Odds ratios for the proteins above were 0.83 (95% CI, 0.79–0.89), 0.59 (95% CI, 0.48–0.71) and 0.88 (95% CI, 0.83–0.94), respectively. In CSF, per 10-fold increase in MMEL1 (OR, 5.03; 95% CI, 3.42–7.41) increased the risk of multiple sclerosis, while SLAMF7 (OR, 0.42; 95% CI, 0.29–0.60) and CD5L (OR, 0.30; 95%CI, 0.18–0.52) decreased the risk. None of the six proteins had reverse causality. Bayesian co-localization suggested that FCRL3 [coloc.abf-posterior probability of hypothesis 4 (PPH4) = 0.889], TYMP (coloc.susie-PPH4 = 0.896), AHSG (coloc.abf-PPH4 = 0.957, coloc.susie-PPH4 = 0.973), MMEL1 (coloc.abf-PPH4 = 0.930) and SLAMF7 (coloc.abf-PPH4 = 0.947) shared the same variant with multiple sclerosis. FCRL3, TYMP and SLAMF7 interacted with target proteins of current multiple sclerosis medications. MMEL1 was replicated in both UK Biobank and FinnGen cohorts. Our integrative analysis suggested that genetically determined levels of circulating FCRL3, TYMP, AHSG, CSF MMEL1 and SLAMF7 had causal effects on multiple sclerosis risk. These findings suggested those five proteins might be promising drug targets for multiple sclerosis and warrant further clinical investigation, especially FCRL3 and SLAMF7.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MR uses genetic variants as instrumental variables, providing robust causal inference and offering insight into the biological pathways driving disease progression [16,17].”
From Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization (2025) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1131 · Cited by 17,749 · cited 1×
“28 In addition, we conducted MR by Wald ratio method and Bayesian co-localization by coloc.abf algorithm with prioritized proteins as both exposure and outcome.”
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728 · cited 7×
“Finally, using the GWAS data from the UK Biobank 13 and FinnGen 14 cohorts and plasma pQTL data from two newly published studies, 15,16 we replicated the analysis as an exter-nal validation to strengthen our conclusion.”
InfluentialDrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404 · cited 1×
“27 We also searched current medications targeting the identified potential causal proteins.”
Mendelian randomization: genetic anchors for causal inference in epidemiological studies
Davey Smith, G., & Hemani, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu328 · Cited by 4,677 · cited 1×
“23 Complete summary statistics for proteins were obtained from three previous studies.”
Giambartolomei, C., Vukcevic, D., Schadt, E. E., Franke, L., Hingorani, A. D., Wallace, C., & Plagnol, V. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004383 · Cited by 4,261 · cited 1×
“…for posterior probability, five proteins identified by MR (FCRL3, TYMP, AHSG, MMEL1 and SLAMF7) were likely to share the same variant of MS. 33 Four of the five identified proteins (FCRL3, TYMP, AHSG and MMEL1) were found to be associated with other traits via phenotype scanning, but none…”
Orienting the causal relationship between imprecisely measured traits using GWAS summary data.
Hemani, G., Tilling, K., & Davey Smith, G. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1007081 · Cited by 2,607 · cited 1×
“We also conducted Steiger filtering to ensure the directionality of the association between proteins and MS. 24 The results were considered statistically significant at P < 0.05.”
InfluentialGenomic atlas of the human plasma proteome
Sun, B. B., Maranville, J. C., Peters, J. E., Stacey, D., Staley, J. R., Blackshaw, J., Burgess, S., Jiang, T., Paige, E., Surendran, P., et al. (2018) · Nature · doi:10.1038/s41586-018-0175-2 · Cited by 2,268 · cited 2×
“12,16,18 The effect was estimated using MR-IVW, MR-Egger, weighted median, simple mode and weighted mode.”
PhenoScanner V2: an expanded tool for searching human genotype–phenotype associations
Kamat, M. A., Blackshaw, J. A., Young, R., Surendran, P., Burgess, S., Danesh, J., Butterworth, A. S., & Staley, J. R. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz469 · Cited by 2,155 · cited 1×
“Phenotype scanning was conducted via both ‘phe-noscanner’ 26 and looking up in the study of Ferkingstad et al .”
Dobson, R., & Giovannoni, G. (2019) · European Journal of Neurology · doi:10.1111/ene.13819 · Cited by 2,148
Guidelines for performing Mendelian randomization investigations
Burgess, S., Davey Smith, G., Davies, N. M., Dudbridge, F., Gill, D., Glymour, M. M., Hartwig, F. P., Holmes, M. V., Minelli, C., Relton, C. L., et al. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15555.1 · Cited by 1,834
Cited by
Åkesson, J., Hojjati, S., Hellberg, S., Raffetseder, J., Khademi, M., Rynkowski, R., Kockum, I. S., Altafini, C., Lubovac-Pilav, Z., Mellergård, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42682-9 · Cited by 116
Does co-localization analysis reinforce the results of Mendelian randomization?
Yin, Q., & Zhu, L. (2023) · Brain · doi:10.1093/brain/awad295 · Cited by 70
Zou, X., Wang, L., Wang, S., Zhang, Y., Ma, J., Chen, L., Li, Y., Yao, T., Zhou, H., Wu, L., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000922 · Cited by 36
“…(such as proteomics) and outcome (IS) in a genetic context and excludes the in fl uence of confounding factors on causality with the aid of multiple sensitivity analyses [9] , and the exclusion of potential confounding factors is one of its advantages over traditional observational studies [10] .”
BackgroundMethodInfluentialProteome-wide mendelian randomization study implicates therapeutic targets in common cancers
Ren, F., Jin, Q., Liu, T., Xuelei, R., & Zhan, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04525-5 · Cited by 39
“…cancer; CCa: colorectal cancer; BLCa: bladder cancer; OCa: ovarian cancer; KCa: kidney cancer; GCa: gastric cancer; cis-pQTL: cis-protein quantitative trait loci; PPH4: posterior probability of hypothesis 4 variation strategy, which utilized genome-wide significant SNPs as genetic instruments [28].”
BackgroundQiu, X., Guo, R., Wang, Y., Zheng, S., Wang, B., & Gong, Y. (2024) · Communications Biology · doi:10.1038/s42003-024-06755-9 · Cited by 24
“…MR (SMR) and two-sample MR (TSMR) enable to estimate pleiotropic or potentially causal associations between genetically determined traits (e.g., gene expression, DNA methylation and protein expression) and complex traits of interest (disease phenotypes as outcomes, e.g., tumors) 16 – 19 .”
Metadata
- Authors
- Lin, J., Zhou, J., & Xu, Y.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Xu, Yan
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-03-02
- Volume
- 146
- Issue
- 8
- Pages
- 3364-3372
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC10393411
- OpenAlex
- W4323035146
- Cited by
- 271
- References
- 56
- Citations by year
- 2026: 43 · 2025: 87 · 2024: 120 · 2023: 21
- FWCI
- 55.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Peking Union Medical College Deposition Research Fund (ZC201904188)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Mapping and Diversity in Plants and Animals
- Keywords
- multiple sclerosis, therapeutic target, plasma proteins, cerebrospinal fluid protein, FCRL3, SLAMF7, CD5L, fetuin-A, thymidine phosphorylase, reverse causality, protein-protein interaction network, autoimmune disease, genetic risk factors, disease progression, relapse prevention, neuroinflammation, neurodegeneration
- MeSH terms
- Bayes Theorem, Humans, Multiple Sclerosis, Phenotype, Polymorphism, Single Nucleotide, Genome-Wide Association Study, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis. https://app.cochat.ai/papers/10.1093/brain/awad070
- The paper
- Lin, J., Zhou, J., & Xu, Y. (2023). Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis. Brain. https://doi.org/10.1093/brain/awad070
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.